Studies on the Interaction between Fibrates and Statins Using Human Hepatic Microsomes

Arzneimittel-Forschung/Drug Research

Volumn 53, Issue 10, 2003, Pages 701-707

  Fujino, Hideki ^a   Shimada, Syunsuke ^a   Yamada, Iwao ^a   Hirano, Masaru ^a   Tsunenari, Yoshihiko ^a   Kojima, Junji ^a  

^a KOWA COMPANY LTD   (Japan)

Author keywords

Atorvastatin; Cerivastatin; Fibrates, interaction with statins; Gemfibrozil; Pitavastatin; Statins, interaction with fibrates

Indexed keywords

BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; PITAVASTATIN; PRAVASTATIN; STATIN;

ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIVER MICROSOME; METABOLIC INHIBITION; PROTEIN BINDING;

EID: 0242383534     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1299815     Document Type: Article

References (31)

1. Kajinami, K., Mabuchi, H., Saito, Y., NK-104, a novel synthetic HMG-CoA reductase inhibitor. Exp. Opin. Invest. Drugs 9, 2653 (2000)
2. Saito, Y., Yamada, N., Teramoto, T., A randomized, double blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 162, 373 (2002)
3. Fruchart, J. C., Brewer, H. B., Jr., Leitersdorf, E., Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am. J. Cardiol. 81, 912 (1998)
4. Davidson, M. H., Combination lipid-lowering therapy in diabetes. Curr. Diab. Rep. 3, 263 (2003)
5. Todd, P. A., Ward, A., Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidemia. Drugs 36, 314 (1988)
6. Duell, P. B., Connor, W. E., Illingworth, D. R., Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am. J. Cardiol. 81, 368 (1998)
7. Ozdemir, O., Boran, M., Gokce, V. et al., A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil conbinationtherapy - a case report. Angiology 51, 695 (2000)
8. Furberg, C. D., Bertram, P., Withdrawal of cerivastatin from the world markets. Curr. Control Traials. Cardiovasc. Med. 2, 205 (2001)
9. Pogson, G. W., Kindred, L. H., Carper, B. D., Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am. J. Cardiol. 83, 1146 (1999)
10. Igel, M., Sudhop, T., Bergmann, K., Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur. J. Clin. Pharmacol. 57, 357 (2001)
11. Backman, J. T., Kyrklund, C., Kivisto, K. T. et al., Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin. Pharmacol. Ther. 68, 122 (2000)
12. Kyrklund, C., Backman, J. T., Kivisto, K. T. et al., Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther. 69, 340 (2001)
13. Kyrklund, C., Backman, J. T., Neuvonen, M. et al., Gemfibrozil greatly increases plasma concentrations of cerivastatin. Abstract of the 6th International Smposium on global risk of coronary heart disease and stroke, Florence/Italy, 67 (2002)
14. Benko, S., Drabant, S., Grezal, G. et al., Pharmacokinetic and bioequivalence study of two gemfibrozil preparations. Arzneim.-Forsch./Drug Res. 47 (II), 913 (1997)
15. Desager, J. P., Horsmans, Y., Vandenplas, C. et al., Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. Atherosclerosis 124, 65 (1996)
16. Castoldi, D., Monzani, V., Tofanetti, O., Determination of bezafibrate in human plasma and urine by high-performance liquid chromatography. J. Chromatogr. 344, 259 (1985)
17. Fujino, H., Yamada, I., Kojima, J. et al., Studies on the metabolic fate of NK-104, a new inhibitor HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human. Xenobiot. Metab. Dispos. 14, 415 (1999).
18. Fujino, H., Saito, T., Tsunenari, Y., Kojima, J., Interaction between several medicines and statins. Arzneim.-Forsch./Drug Res. 53 (I), 145 (2003)
19. Christians, U., Jacobsen, W., Floren, L., Metabolism and drug interactions 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor in transplant patients: Are the statins mechanistcally similar? Pharmacol. Ther. 80, 1 (1998)
20. Fischer, V., Johanson, L., Heitz, F. et al., The 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab. Dispos. 27, 410 (1999)
21. Kimata, H., Fujino, H., Koide, T. et al., Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats. Xenobiot. Metab. Dispos. 13, 484 (1998)
22. Jemal, M., Rao, S., Salahudeen, I. et al., Quantitation of cerivastatin and its seven acid and lactone biotransformation products in human serum by liquid chromatography-elec-trospray tandem mass spectrometry. J. Chromatogr. (B) 736, 19 (1999)
23. Jemal, M., Ouyang, Z., Chen, B.C., Teitz, D., Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-perform-ance liquid chromatography with electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom. 13, 1003 (1999)
24. Gonzalez-Penas, E., Agarraberes, S., Lopez-Ocariz, A. et al., A sensitive method for the determination of gemfibrozil in human plasma samples by RP-LC. J. Pharm. Biomed. Anal. 26, 7 (2001)
25. Ludwig, E., Wolfinger, H., Ebner, T., Assessment of microsomal tolbutamide hydroxylation by a simple thin-layer chromatography radioactivity assay. J. Chromatogr. (B) 707, 347 (1998)
26. Fujino, H., Yamada, I., Shimada, S. et al., Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin layer chromatography assay-inhibitory effect of NK-104, a new inhibitor of HMG-CoA reductase. J. Chromatogr. (B) 757, 143 (2001)
27. Fujino, H., Yamada, I., Shimada, S. et al., Metabolic fate of pitavastatin (NK-104), a new inhibitor of HMG-CoA reductase: Effects on drug-metabolizing systems in rats and humans. Arzneim.- Forsch./Drug Res. 52 (II), 745 (2002)
28. Lozada, A., Dujovne, C. A., Drug interactions with fibric acids. Pharmacol. Ther. 63, 163 (1994)
29. Dix, K. J., Coleman, D. P., Jeffcoat, A. R., Comparative metabolism and disposition of gemfibrozil in male and female Sprague-Dawley rats and Syrian golden hamsters. Drug Metab. Dispos. 27, 138 (1998)
30. Wen, X., Wang, J. S., Backman, J. T. et al., Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab. Dispos. 29, 1359 (2001)
31. Mück, W., Clinical pharmacokinetics of cerivastatin. Clin. Pharmacokinet. 39, 99 (2000)